

**North County Neurology Associates/
The Research Center of Southern California.**
6010 Hidden Valley Road, Ste. 200
Carlsbad, CA 92011
Phone: 760-631-3000
Fax: 760-631-3016



Andrew Bierman MSN, APRN, FNP-C

EDUCATION

- | | |
|---|---------------------|
| Azusa Pacific University Master of Science in Nursing – Family Nurse Practitioner | ■ 01/2017 – 05/2019 |
| Azusa Pacific University Bachelors of Science in Nursing | ■ 05/2014 – 11/2015 |
-
-

CERTIFICATION & LICENSURE

- | | |
|---|----------|
| California Registered Nurse License – 95079847 | ■ Active |
| California Nurse Practitioner License – 95011909 | ■ Active |
| California Nurse Practitioner Furnishing – 95011909 | ■ Active |
| American Academy of Nurse Practitioners – F06190629 | ■ Active |
| DEA Registration – MB5378991 | ■ Active |
| American Heart Association BLS | ■ Active |
-
-

PROFESSIONAL EXPERIENCE

- | | |
|--|---------------------|
| Nurse Practitioner North County Neurology Associates dba The Neurology Center Carlsbad, CA Medical | ■ 07/2019 – Present |
| Research Sub-Investigator North County Neurology Associates dba The Neurology Center Carlsbad, CA | ■ 08/2019 – Present |
| Telemetry RN / Relief Charge Nurse La Palma Intercommunity Hospital, La Palma, CA | ■ 02/2016 – 07/2019 |
| Home Health Registered Nurse Mission Home Health, Irvine, CA | ■ 08/2017 – 12/2017 |
| Period of lapse in employment after graduate education Reason: RN Boards testing and employment search | ■ 11/2015 – 02/2016 |

HOSPITAL AFFILIATIONS

| | |
|---|---------------------|
| Scripps Memorial Hospital , Encinitas, California | ■ 12/2019 – Present |
| Scripps Memorial Hospital , La Jolla, California | ■ Pending |
| Palomar Medical Center , Escondido & Poway, California | ■ 02/2020 – Present |
| Tri-City Medical Center , Oceanside, California | ■ 11/2019 – Present |

AWARDS

| | |
|---|---------------------|
| HRSA Federally Qualified Health Center ANEW Grant | ■ 01/2017 – 12/2017 |
| Outstanding Graduate Award – Azusa Pacific University | ■ 05/04/2019 |

PROFESSIONAL SOCIETIES

| | |
|---|------------------|
| American Association of Nurse Practitioners | ■ 2018 – Present |
| California Association of Nurse Practitioners | ■ 2018 – Present |

RESEARCH ACTIVITIES

Disparities amongst Women with Preserved Ejection Fraction Heart Failure - 2019

Alzheimer's disease

251AD201: Randomized, Double Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability and Efficacy of BIIB092 in Subjects with Mild Cognitive Impairment due to Alzheimer's Disease or with Mild Alzheimer's Disease. Sub- Investigator – 2019

I5T-MC-AACI. Assessment of safety, tolerability, and efficacy of Donanemab in early symptomatic Alzheimer's disease. Sub-Investigator– 2020

Migraine

A Parallel Group Double Blind Randomized Placebo- Controlled Study to Evaluate the Efficacy and Safety of Eptinezumab Administered Intravenously in Subjects Experiencing an Acute Attack of Migraine. Protocol Number ALD403-CLIN-015. Sub-Investigator – 2019

Multiple Sclerosis

BN42082: A phase IIIB multicenter, randomized double blind, controlled study to evaluate the efficacy, safety and pharmacokinetics of a higher dose of Ocrelizumab in adults with relapsing multiple sclerosis. Sub-Investigator - 2019

RESEARCH ACTIVITIES CONT'D

Multiple Sclerosis *Continued*

GN41851. A phase III multicenter, randomized, double blind, double-dummy, parallel-group study to evaluate the efficacy and safety of Fenebrutinib compared with Teriflunomide in adult patients with relapsing Multiple Sclerosis. Sub-Investigator - 2020

ABBVIE M14-397 – MS Safety and Efficacy study of Elezanumab (ABT-555) in Progressive Forms of MS. Sub-Investigator – 2019

ABBVIE M18-918 – MS Safety and Efficacy study of Elezanumab (ABT-555) in Relapsing Forms of MS. Sub-Investigator – 2019

Myasthenia Gravis

ARGX-113-1704. A Randomized, Double Blind, Placebo-Controlled, Multicenter Phase 3 Trial to Evaluate the Efficacy, Safety and Tolerability of ARGX-113 in Patients with Myasthenia Gravis Having Generalized Muscle Weakness. Sub-Investigator – 2019

ARGX-113-1705. A Long-Term, Single-Arm, Open-Label, Multicenter, Phase 3 Follow-on Trial of ARGX-113-1704 to Evaluate the Safety and Tolerability of ARGX-113 in Patients with Myasthenia Gravis having Generalized Muscle Weakness. Sub-Investigator – 2020

Other

Alexion ECU-NMO-302: A Phase III, Open-Label, Extension Trial of ECU-NMO-301 to Evaluate the Safety and Efficacy of Eculizumab in Patients with Relapsing Neuromyelitis Optica (NMO) Sub-Investigator - 2019

ALXN-1210-NMO-307: A phase 3, external placebo-controlled, open label, multicenter study to evaluate the efficacy and safety of Ravulizumab in adult patients with Neuromyelitis Optica Spectrum Disorder (NMOSD). Sub-Investigator - 2020